De Luca Vincenzo, Chaudhary Zanib, Al-Chalabi Nzaar, Qian Jessica, Borlido Carol, Gerretsen Philip, Graff Ariel, Remington Gary, Chintoh Araba
Department of Psychiatry, CAMH, University of Toronto, 250 College St, Toronto, M5T1R8, Canada.
J Neural Transm (Vienna). 2023 Feb;130(2):165-169. doi: 10.1007/s00702-022-02585-3. Epub 2023 Jan 17.
Various studies have investigated the relationship between genetic polymorphisms of antipsychotic drug-metabolizing agents and drug response. DNA methylation is a form of epigenetic modification that regulates gene expression. Few studies have analyzed the relationship between genome-wide methylation patterns and treatment resistance schizophrenia. The primary aim of this pilot study is to investigate the association between treatment resistance status and genome-wide DNA methylation in schizophrenia patients. Treatment resistance status was determined for 109 patients with schizophrenia. Treatment resistance was the primary outcome variable in a model, including methylation status of white blood cells using the Illumina 450 array. The genome-wide DNA methylation levels in 109 Schizophrenia subjects did not show that DNA methylation sties were associated with resistance status. From our study, it is evident the importance of continuing to investigate the relationship between DNA methylation and antipsychotic response to personalize treatment in schizophrenia. Future studies require larger prescription databases to build on the results presented in this pilot study.
多项研究探讨了抗精神病药物代谢相关基因多态性与药物反应之间的关系。DNA甲基化是一种调控基因表达的表观遗传修饰形式。很少有研究分析全基因组甲基化模式与难治性精神分裂症之间的关系。这项初步研究的主要目的是调查精神分裂症患者的治疗抵抗状态与全基因组DNA甲基化之间的关联。对109例精神分裂症患者确定了治疗抵抗状态。治疗抵抗是一个模型中的主要结局变量，该模型包括使用Illumina 450芯片检测白细胞的甲基化状态。109例精神分裂症患者的全基因组DNA甲基化水平并未显示DNA甲基化位点与抵抗状态相关。从我们的研究中可以明显看出，继续研究DNA甲基化与抗精神病反应之间的关系对于精神分裂症个性化治疗的重要性。未来的研究需要更大的处方数据库，以基于这项初步研究的结果进一步开展研究。
